ALPHAMAB ONCOLO.DL-000002 Financial Flexibility Index
ALPHAMAB ONCOLO.DL-000002 financial flexibility index. ALPHAMAB ONCOLO.DL-000002 (3NK) has a Financial Flexibility Index of -0.23x as of December 2025. Free cash flow of €-90.30 Million (operating CF €-121.89 Million minus capex €31.59 Million) represents 0% of total liabilities (€386.17 Million). See how much free cash does ALPHAMAB ONCOLO.DL-000002 generate to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of ALPHAMAB ONCOLO.DL-000002 (2021–2025)
Financial flexibility index of ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025. Historical Financial Flexibility Index trend for ALPHAMAB ONCOLO.DL-000002 across 5 annual periods. Check 3NK cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
ALPHAMAB ONCOLO.DL-000002 Financial Flexibility Index by Year (2021–2025)
ALPHAMAB ONCOLO.DL-000002 financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for ALPHAMAB ONCOLO.DL-000002. For the full cash flow conversion analysis, see ALPHAMAB ONCOLO.DL-000002 (3NK) cash conversion ratio.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.23x | €-90.30 Million | €-121.89 Million | €386.17 Million | ▼ -140.9% |
| 2024 | 0.57x | €234.11 Million | €212.34 Million | €409.87 Million | ▲ +259.4% |
| 2023 | -0.36x | €-166.66 Million | €-202.84 Million | €465.00 Million | ▼ -17.6% |
| 2022 | -0.30x | €-170.66 Million | €-300.31 Million | €559.86 Million | ▼ -56.6% |
| 2021 | -0.19x | €-162.48 Million | €-320.60 Million | €834.80 Million | — |